Michael A. Zasloff
Known title: DirectorCIK: 0001033511
Associated companies
Transaction History
| AMPH | ▲ Buy | Grant | 8,143 | $0 | 6/1/2026 | View on chart |
| AMPH | ▲ Buy | Grant | 5,122 | $0 | 6/2/2025 | View on chart |
| AMPH | ▲ Buy | Grant | 3,076 | $0 | 6/3/2024 | View on chart |
| AMPH | ▼ Sell | Open Market | 3,111 | $148K | 3/5/2024 | View on chart |
| AMPH | ▼ Sell | Open Market | 9,389 | $442K | 3/5/2024 | View on chart |
| AMPH | ▼ Sell | Open Market | 12,759 | $730K | 8/15/2023 | View on chart |
| AMPH | ▲ Buy | Grant | 2,716 | $0 | 6/5/2023 | View on chart |
| AMPH | ▼ Sell | Open Market | 7,500 | $316K | 5/15/2023 | View on chart |
| AMPH | ▲ Buy | Grant | 4,163 | $0 | 6/10/2022 | View on chart |
| AMPH | ▼ Sell | Open Market | 10,291 | $366K | 5/16/2022 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 10,291 | $176K | 5/16/2022 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 10,000 | $171K | 3/16/2022 | View on chart |
| AMPH | ▼ Sell | Open Market | 10,000 | $337K | 3/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Amphastar (AMPH) Cited as Safe-and-Steady Stock in Yahoo Analysis
A recent Yahoo Finance article highlighted Amphastar Pharmaceuticals as a 'safe-and-steady' stock worth researching further. This positive framing contrasts with other companies facing challenges, suggesting the market views AMPH as a relatively stable option. The stock currently trades with a trailing P/E of 14.2, which is lower than the average analyst target price of $22.50.
Amphastar (AMPH) Cited as Safe-and-Steady Stock in Yahoo Analysis. A recent Yahoo Finance article highlighted Amphastar Pharmaceuticals as a 'safe-and-steady' stock worth researching further. This positive framing contrasts with other companies facing challenges, suggesting the market views AMPH as a relatively stable option. The stock currently trades with a trailing P/E of 14.2, which is lower than the average analyst target price of $22.50.